 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H25NO |
| Molar mass | 295.426 g·mol−1 |
| 3D model (JSmol) | |
| |
Difemetorex (INN) ordiphemethoxidine (USAN) is acentral nervous system (CNS)stimulantdrug introduced inFrance in 1966 by the pharmaceutical company,Ciba-Geigy; it was briefly used as anappetite suppressant andweight loss aid into the early 1970s, sold under thebrand nameCleofil. A member of thepiperidinechemical class, difemetorex was described as having such a disruptive and intolerable side effect ofinsomnia that patientdrug compliance suffered and frequency of clinical use decreased, resulting in withdrawal from the market and cessation of production, availability, accessibility, and overall recognition among related substances. It is only known to have been marketed in France, and has remained virtually non-existent in the current era.[1][2][3][4][5][6]
Alkylation ofdesoxypipradrol withethylene oxide gives difemetorex.[7]
